Novavax, Inc. (NASDAQ:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that it will host its 3rd annual Analyst and Investor Meeting on Tuesday, September 29, 2015 from 9:00 a.m. – 11:00 a.m. ET in New York, NY.
Senior management will conduct a series of presentations to update analysts and investors on the Company’s ongoing clinical development programs. In addition, a key opinion leader will provide a clinical perspective on respiratory syncytial virus (RSV) disease. (Original Source)
Shares of Novavax closed yesterday at $9.91. NVAX has a 1-year high of $15.01 and a 1-year low of $3.92. The stock’s 50-day moving average is $11.38 and its 200-day moving average is $9.95.
On the ratings front, Novavax has been the subject of a number of recent research reports. In a report issued on August 11, Piper Jaffray analyst Edward Tenthoff reiterated a Buy rating on NVAX, with a price target of $17, which represents a potential upside of 71.5% from where the stock is currently trading. Separately, on the same day, J.P. Morgan’s Cory Kasimov reiterated a Buy rating on the stock and has a price target of $14.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Edward Tenthoff and Cory Kasimov have a total average return of 17.9% and 3.5% respectively. Tenthoff has a success rate of 50.8% and is ranked #269 out of 3768 analysts, while Kasimov has a success rate of 46.1% and is ranked #1029.
Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.